Three studies examine how resistance to chemotherapy develops in cancers deficient in BRCA1 and BRCA2. The mechanism involves restoration of BRCA1 and BRCA2 activity. Shah examines the implications for the clinic, such as the potential value of continuing treatment with cisplatin and similar agents even after drug resistance develops.
This is a preview of subscription content, log in via an institution to check access.
References
Sakai, W. et al. Nature 451, 1116–1120 (2008).
Edwards, S.L. et al. Nature 451, 1111–1115 (2008).
Swisher, E.M. et al. Cancer Res. 68, 2581–2586 (2008).
Aletti, G.D., Gallenberg, M.M., Cliby, W.A., Jatoi, A. & Hartmann, L.C. Mayo Clin. Proc. 82, 751–770 (2007).
Farmer, H. et al. Nature 434, 917–921 (2005).
Bryant, H.E. et al. Nature 434, 913–917 (2005).
Taniguchi, T. et al. Nat. Med. 9, 568–574 (2003).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Shah, N.P. & Sawyers, C.L. Oncogene 22, 7389–7395 (2003).
Skorski, T. Oncogene 21, 8591–8604 (2002).
Druker, B.J. et al. N. Engl. J. Med. 355, 2408–2417 (2006).
Shah, N.P. et al. J. Clin. Invest. 117, 2562–2569 (2007).
Herzog, T.J., Coleman, R.L., Markman, M., Cella, D. & Thigpen, J.T. Gynecol. Oncol. 102, 218–225 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
N.P.S. has served as a consultant for Bristol-Myers Squibb (manufacturer of cisplantin) and Novartis (manufacturer of imatinib).
Rights and permissions
About this article
Cite this article
Shah, N. BRCA: From therapeutic target to therapeutic shield. Nat Med 14, 495–496 (2008). https://doi.org/10.1038/nm0508-495
Issue Date:
DOI: https://doi.org/10.1038/nm0508-495
- Springer Nature America, Inc.